3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Conditions
Neoplasms
14
Carcinoma, Non-Small-Cell Lung
8
Sarcoma
6
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Neuroblastoma
6
Multiple Myeloma
6
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Melanoma
5
Ovarian Neoplasms
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Breast Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Hematologic Neoplasms
3
Head and Neck Neoplasms
3
Urinary Bladder Neoplasms
2
Primary Myelofibrosis
2
Pheochromocytoma
2
Osteosarcoma
2
Non-Muscle Invasive Bladder Neoplasms
2
Neuroectodermal Tumors, Primitive
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Interventions
burosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
Expanded_access
×
Familial Hypophosphatemic Rickets
×
Clear all
NCT03775187
2025-03-05
Expanded Access to Burosumab
Kyowa Kirin Co., Ltd.
Available